

# Pharmaceutical Drug Delivery Market by Route of Administration [Oral, Injectors (Pen, Auto Injectors) Implantable, Syrups, Gels, Pulmonary, Tablets, Syringes], Application (Cancer, Diabetes), Facility of Use (Hospital, Home Care) -Global Forecast to 2029

<https://marketpublishers.com/r/DFAB11EB95DEN.html>

Date: September 2024

Pages: 719

Price: US\$ 4,950.00 (Single User License)

ID: DFAB11EB95DEN

## Abstracts

The global pharmaceutical drug delivery market is projected to reach USD 2,546.0 billion by 2029 from USD 1,949.4 billion in 2024 at a CAGR of 5.5% during the forecast period. The rapid growth in the geriatric population globally and the significant rise in the patients with chronic diseases are expected to boost the demand for pharmaceutical drug delivery market. Moreover, gradual rise in utilization of home care and self administration is likely to support the market growth. Advancements in drug delivery technology, new product launches, robust pharmaceutical R&D investments by key companies and government policies, investments in healthcare infrastructure, and initiatives to enhance the accessibility and affordability of drug delivery products is anticipated to fuel the market growth.

“The injectable drug delivery segment of pharmaceutical drug delivery market to grow with the highest CAGR during the forecast period.”

Based on the pharmaceutical drug delivery market, the injectable drug delivery segment is anticipated to grow at significant rate during forecast period. Due to increasing prevalence of chronic disease. Injectables are used in many therapeutic areas, such as hormonal disorders, oncology, autoimmune diseases, and orphan diseases. The injectable route is a promising alternative over oral drug delivery. Moreover it also maximize patient compliance, and reduce the frequency of dosage administration. Also, Due to increased preference in self-administration and home care, there has been significant development and advancement in injectables that have helped in minimizing

the exposure of needles as well as the pain associated with them. These factors are fostering the growth of injectable drug delivery at higher pace.

“The Cancer segment to capture the largest market share of pharmaceutical drug delivery market.”

Based on application the Pharmaceutical drug delivery market are segmented into infectitious diseases, cancer, autoimmune disease, diabetes other disease indications The cancer segment held the largest market share during the forecast period. Cancer forms a key therapeutic application segment for drug delivery technologies. Pharmaceutical drug delivery technologies are widely used in various therapies, such as chemotherapy, hormone therapy, target therapy, and immunotherapy. The incidence of cancer has surged rapidly across the globe. According to the WHO, in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. Owing to this, companies are increasingly focusing on developing novel medicines for cancer; this is expected to drive the growth of this therapeutic segment.

“North America accounted for the largest share of the pharmaceutical drug delivery market by region.”

The global pharmaceutical drug delivery market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest regional market for pharmaceutical drug delivery products and services , whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.

The largest share of North America can be attributed to the high disease burden of chronic disease contributing to a larger pool of patients requiring pharmaceutical drug delivery products. The presence of numerous potentialphaemaceutical giants ,surge in medical procedures , and favorable reimbursement policy in the region is likely to promote the growth of pharmaceutical drug delivery market in North America.

A breakdown of the primary participants referred to for this report is provided below:

By Company Type: Tier 1–35%, Tier 2–45%, and Tier 3– 20%

By Designation: C-level–35%, Director-level–25%, and Others–40%

By Region: North America–45%, Europe–30%, Asia Pacific–20%, Latin

America–3%, and the Middle East & Africa–2%

The major players operating in the pharmaceutical drug delivery market are Johnson & Johnson services, inc (US), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Pfizer Inc. (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), Sanofi (France), Bayer AG (Germany), Amgen, Inc. (US).

### Research Coverage

This report studies the pharmaceutical drug delivery market based on pharmaceutical drug delivery, route of administration, application, facility of use and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

### Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

Analysis of Key drivers (increasing prevalence of chronic disease, technological advancement in pharmaceutical drug delivery technologies, new product launches, growing investments in pharmaceutical R&D), restraints (high cost of development, risk of needlestick injuries) , Opportunities (emerging markets, gradual shift towards homecare and self administration) , Challenge (pricing pressure)

Market Penetration: Comprehensive information on the product portfolios offered by the top players in the pharmaceutical drug delivery market

Product Development/Innovation: Detailed insights on the upcoming trends,

R&D activities, and product launches in the pharmaceutical drug delivery market

Market Development: Comprehensive information on lucrative emerging regions

Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the pharmaceutical drug delivery market

Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

## Contents

### **1 INTRODUCTION**

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
  - 1.2.1 INCLUSIONS & EXCLUSIONS
- 1.3 STUDY SCOPE
  - 1.3.1 MARKETS COVERED
  - 1.3.2 YEARS CONSIDERED
  - 1.3.3 CURRENCY CONSIDERED
- 1.4 MAJOR STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES

### **2 RESEARCH METHODOLOGY**

- 2.1 RESEARCH APPROACH
  - 2.1.1 SECONDARY RESEARCH
    - 2.1.1.1 Key data from secondary sources
  - 2.1.2 PRIMARY RESEARCH
    - 2.1.2.1 Insights from primary experts
    - 2.1.2.2 Breakdown of primaries
- 2.2 MARKET SIZE ESTIMATION
- 2.3 MARKET SHARE ESTIMATION
- 2.4 STUDY ASSUMPTIONS

### **3 EXECUTIVE SUMMARY**

### **4 PREMIUM INSIGHTS**

- 4.1 PHARMACEUTICAL DRUG DELIVERY MARKET OVERVIEW
- 4.2 ASIA PACIFIC: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE AND COUNTRY
- 4.3 PHARMACEUTICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

### **5 MARKET OVERVIEW**

- 5.1 MARKET DYNAMICS

### 5.1.1 DRIVERS

- 5.1.1.1 Rising prevalence of chronic diseases
- 5.1.1.2 Technological advancements and product launches
- 5.1.1.3 Rising investments in pharmaceutical R&D
- 5.1.1.4 Growing emphasis on patient convenience
- 5.1.1.5 Government initiatives to boost affordability

### 5.1.2 RESTRAINTS

- 5.1.2.1 High development costs

### 5.1.3 OPPORTUNITIES

- 5.1.3.1 Increased preference for self-administration and home care
- 5.1.3.2 Rising interest in biosimilars and biologics
- 5.1.3.3 Market opportunities in emerging economies
- 5.1.3.4 Development of biocompatible materials for drug delivery systems

### 5.1.4 CHALLENGES

- 5.1.4.1 Pricing pressure from governing bodies
- 5.1.4.2 Risk of needlestick injuries

## 5.2 REGULATORY LANDSCAPE

### 5.2.1 NORTH AMERICA

- 5.2.1.1 US
- 5.2.1.2 Canada

### 5.2.2 EUROPE

- 5.2.2.1 Germany
- 5.2.2.2 Italy
- 5.2.2.3 France
- 5.2.2.4 UK

- 5.2.2.5 Switzerland

### 5.2.3 ASIA PACIFIC

- 5.2.3.1 China
- 5.2.3.2 Japan
- 5.2.3.3 India
- 5.2.3.4 South Korea
- 5.2.3.5 Australia

### 5.2.4 LATIN AMERICA

### 5.2.5 MIDDLE EAST & AFRICA

### 5.2.6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

## 5.3 VALUE CHAIN ANALYSIS

## 5.4 SUPPLY CHAIN ANALYSIS

### 5.4.1 PROMINENT COMPANIES

- 5.4.2 SMALL & MEDIUM-SIZED COMPANIES
- 5.4.3 END USERS
- 5.5 ECOSYSTEM ANALYSIS
- 5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.7 TECHNOLOGY ANALYSIS
  - 5.7.1 KEY TECHNOLOGIES
  - 5.7.2 AUTOMATED INSULIN DELIVERY (AID)
    - 5.7.2.1 Wearable patches
    - 5.7.2.2 On-body drug delivery systems
    - 5.7.2.3 Needle-free drug delivery systems
    - 5.7.2.4 3D printing
    - 5.7.2.5 Responsive hydrogels
    - 5.7.2.6 Exosomes and extracellular vesicles
    - 5.7.2.7 Polymeric particles and implants
    - 5.7.2.8 Atomic layer deposition
    - 5.7.2.9 Ingestible injectables
    - 5.7.2.10 Ocular drug delivery
  - 5.7.3 COMPLEMENTARY TECHNOLOGIES
    - 5.7.3.1 Pen injectors
    - 5.7.3.2 Prefilled syringes
    - 5.7.3.3 Autoinjector technology
    - 5.7.3.4 Nanotechnology
- 5.8 TRADE ANALYSIS
  - 5.8.1 TRADE ANALYSIS FOR SYRINGES, WITH OR WITHOUT NEEDLES, USED IN MEDICAL, SURGICAL, DENTAL, OR VETERINARY SCIENCES
  - 5.8.2 TRADE ANALYSIS FOR MEDICAMENTS IN MEASURED DOSES, INCLUDING TRANSDERMAL ADMINISTRATION
- 5.9 PATENT ANALYSIS
  - 5.9.1 PATENT PUBLICATION TRENDS FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES
  - 5.9.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
- 5.10 PORTER'S FIVE FORCES ANALYSIS
  - 5.10.1 THREAT OF NEW ENTRANTS
  - 5.10.2 THREAT OF SUBSTITUTES
  - 5.10.3 BARGAINING POWER OF SUPPLIERS
  - 5.10.4 BARGAINING POWER OF BUYERS
  - 5.10.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.11 KEY STAKEHOLDERS & BUYING CRITERIA
  - 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS

- 5.11.2 BUYING CRITERIA
- 5.12 PRICING ANALYSIS
- 5.13 KEY CONFERENCES & EVENTS (2024–2025)
- 5.14 REIMBURSEMENT ANALYSIS
- 5.15 CASE STUDY ANALYSIS
- 5.16 INVESTMENT & FUNDING SCENARIO
- 5.17 UNMET NEEDS IN PHARMACEUTICAL DRUG DELIVERY MARKET
- 5.18 END-USER EXPECTATIONS IN PHARMACEUTICAL DRUG DELIVERY MARKET
- 5.19 AI INTEGRATION IN PHARMACEUTICAL DRUG DELIVERY MARKET

## **6 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION**

### 6.1 INTRODUCTION

### 6.2 INJECTABLE DRUG DELIVERY

#### 6.2.1 CONVENTIONAL INJECTION DEVICES

##### 6.2.1.1 Conventional injection devices market, by material

###### 6.2.1.1.1 Glass syringes

###### 6.2.1.1.1.1 Durability and safety to drive adoption

###### 6.2.1.1.2 Plastic syringes

###### 6.2.1.1.2.1 Lower price compared to glass syringes to propel adoption

##### 6.2.1.2 Conventional injection devices market, by product

###### 6.2.1.2.1 Fillable syringes

6.2.1.2.1.1 Ease of use and variable dosing formulations of fillable syringes to drive market

###### 6.2.1.2.2 Prefilled syringes

6.2.1.2.2.1 Improved dose accuracy and increased patient convenience & safety to support usage

##### 6.2.1.3 Conventional injection devices market, by usability

###### 6.2.1.3.1 Reusable syringes

###### 6.2.1.3.1.1 Ease of use, dismantling, and cleaning to support market growth

###### 6.2.1.3.2 Disposable syringes

###### 6.2.1.3.2.1 Low cost and convenience to favor end-user demand

#### 6.2.2 SELF-INJECTION DEVICES

##### 6.2.2.1 Needle-free injectors

6.2.2.1.1 Rapid drug delivery and better reproducibility than invasive drug delivery systems to support market growth

##### 6.2.2.2 Autoinjectors



6.2.2.2.1 Improved patient satisfaction compared to manual injections to drive market

6.2.2.3 Pen injectors

6.2.2.3.1 Need for multi-dose devices to propel adoption

6.2.2.4 Wearable injectors

6.2.2.4.1 Increasing adoption of home infusion therapy and rising focus on cost-curtailment in healthcare to support market growth

## 6.3 ORAL DRUG DELIVERY

### 6.3.1 SOLID ORAL DRUGS

6.3.1.1 Tablets

6.3.1.1.1 Development of mini-tablets to propel market growth

6.3.1.2 Capsules

6.3.1.2.1 Easy absorption of drugs and decreased irritation in GI tract drive capsule usage

6.3.1.3 Oral powders

6.3.1.3.1 Convenience for patients with trouble swallowing other dosage forms to propel usage

6.3.1.4 Pills

6.3.1.4.1 Rising incidence of target ailments to propel market growth

### 6.3.2 LIQUID ORAL DRUGS

6.3.2.1 Oral syrups

6.3.2.1.1 Ease of administration to drive usage

6.3.2.2 Oral solutions

6.3.2.2.1 Rising preference among geriatric and pediatric patients to support adoption

6.3.2.3 Oral emulsions

6.3.2.3.1 Enhanced solubility, stability, and ease of administration to drive market

6.3.2.4 Oral elixirs

6.3.2.4.1 Rising preference in pediatric cases to drive market

### 6.3.3 SEMI-SOLID ORAL DRUGS

6.3.3.1 Oral gels

6.3.3.1.1 Controlled drug release benefits to propel usage

6.3.3.2 Oral pastes

6.3.3.2.1 Protection against oxidation and enzymatic hydrolysis to support adoption

## 6.4 TOPICAL DRUG DELIVERY

### 6.4.1 SEMI-SOLID TOPICAL FORMULATIONS

6.4.1.1 Topical creams

6.4.1.1.1 Variable efficacy to affect end-user adoption

6.4.1.2 Topical gels

6.4.1.2.1 Faster drug release and greater patient acceptability to drive the market for topical gels

6.4.1.3 Topical ointments

6.4.1.3.1 Wide usage in analgesic indications to drive market

6.4.1.4 Topical pastes

6.4.1.4.1 Wide usage in treating/preventing skin irritation to support growth

6.4.1.5 Topical lotions

6.4.1.5.1 Ease of administration of lotions to drive demand

#### 6.4.2 LIQUID TOPICAL FORMULATIONS

6.4.2.1 Topical suspensions

6.4.2.1.1 High bioavailability and controlled onset of action to support adoption

6.4.2.2 Topical emulsions

6.4.2.2.1 Improved spreadability, stability, and controlled release of active ingredients

6.4.2.3 Topical solutions

6.4.2.3.1 Ease of use and ready availability to support market growth

#### 6.4.3 SOLID TOPICAL FORMULATIONS

6.4.3.1 Topical powders

6.4.3.1.1 Rising incidence of skin disorders to drive market

6.4.3.2 Suppositories

6.4.3.2.1 Compatibility and stability to support growth

#### 6.4.4 TRANSDERMAL PRODUCTS

6.4.4.1 Transdermal patches

6.4.4.1.1 Prevention of premature metabolization of drugs to drive market

6.4.4.2 Transdermal gels

6.4.4.2.1 Rapid drug release capabilities to support usage of gels

6.4.4.3 Transdermal sprays

6.4.4.3.1 Simplicity and noninvasive nature to support adoption

### 6.5 OCULAR DRUG DELIVERY

#### 6.5.1 LIQUID OCULAR FORMULATIONS

6.5.1.1 Eye drops

6.5.1.1.1 Rising prevalence of cataracts and other eye diseases to drive market growth

6.5.1.2 Liquid ocular sprays

6.5.1.2.1 Benefits over eye drops to support market growth

#### 6.5.2 SEMI-SOLID OCULAR FORMULATIONS

6.5.2.1 Ocular gels

6.5.2.1.1 High viscosity, prolonged drug release, and ease of drug administration to support market growth

#### 6.5.2.2 Eye ointments

##### 6.5.2.2.1 Safety and efficient administration to drive market

#### 6.5.3 OCULAR DEVICES

##### 6.5.3.1 Ocular inserts

##### 6.5.3.1.1 Support for sustained drug release to drive adoption

##### 6.5.3.2 Drug-coated contact lenses

##### 6.5.3.2.1 Better eyesight offered by lenses and high compliance to drive market

#### 6.6 PULMONARY DRUG DELIVERY

##### 6.6.1 METERED-DOSE INHALERS

##### 6.6.1.1 Support for coordinating inhaler actuation and patient breath to drive adoption

##### 6.6.2 DRY POWDER INHALERS

##### 6.6.2.1 Chemical stability of formulations to support usage

##### 6.6.3 NEBULIZERS

##### 6.6.3.1 Jet nebulizers

##### 6.6.3.1.1 Jet nebulizers to account for largest share of nebulizers market

##### 6.6.3.2 Ultrasonic nebulizers

##### 6.6.3.2.1 Ease of use and comfort for patients to propel adoption

##### 6.6.3.3 Soft mist nebulizers

##### 6.6.3.3.1 Rising preference in COPD treatment to propel market

#### 6.7 NASAL DRUG DELIVERY

##### 6.7.1 NASAL SPRAYS

6.7.1.1 Applications in relieving nasal congestion, runny nose, itchy nose, and sneezing to support adoption

##### 6.7.2 NASAL DROPS

##### 6.7.2.1 Efficiency over nasal sprays to drive adoption

##### 6.7.3 NASAL GELS

##### 6.7.3.1 Long-lasting relief and reduced irritation to support growth

##### 6.7.4 NASAL POWDERS

##### 6.7.4.1 Absence of preservatives and stability of formulations to support adoption

#### 6.8 TRANSMUCOSAL DRUG DELIVERY

##### 6.8.1 ORAL TRANSMUCOSAL FORMULATIONS

##### 6.8.2 BUCCAL DRUG DELIVERY

##### 6.8.2.1 Applications in local and systematic therapies to drive adoption

##### 6.8.2.2 Sublingual drug delivery

##### 6.8.2.2.1 High rate of adoption to propel usage

##### 6.8.3 OTHER TRANSMUCOSAL FORMULATIONS

##### 6.8.3.1 Rectal drug delivery

##### 6.8.3.1.1 High vascularization to support rapid drug absorption

##### 6.8.3.2 Vaginal drug delivery

6.8.3.2.1 Higher permeability and drug stability to drive market

## 6.9 IMPLANTABLE DRUG DELIVERY

### 6.9.1 PASSIVE IMPLANTABLE DRUG DELIVERY

6.9.1.1 Targeted drug delivery benefits to propel market

### 6.9.2 ACTIVE IMPLANTABLE DRUG DELIVERY

6.9.2.1 Need for better diagnostic monitoring and body fluid transportation to favor market growth

## 7 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION

### 7.1 INTRODUCTION

### 7.2 INFECTIOUS DISEASES

7.2.1 HIGH BURDEN OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH

### 7.3 CANCER

7.3.1 GROWING INCIDENCE OF CANCER TO ENSURE DEMAND FOR THERAPY

### 7.4 CVD

7.4.1 INCREASING PREVALENCE AND INCREASING INNOVATION IN DRUG DELIVERY TECHNOLOGIES TO PROPEL MARKET GROWTH

### 7.5 DIABETES

7.5.1 EMERGENCE OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH

### 7.6 RESPIRATORY DISEASES

7.6.1 HIGH PREVALENCE OF ASTHMA AND COPD TO DRIVE ADOPTION OF PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES

### 7.7 CNS DISORDERS

7.7.1 WIDE USAGE OF ORAL AND INJECTABLE DRUG DELIVERY SYSTEMS TO DRIVE MARKET

### 7.8 AUTOIMMUNE DISEASES

7.8.1 AUTOIMMUNE DISEASES TO REGISTER HIGHEST GROWTH

### 7.9 OTHER APPLICATIONS

7.9.1 OPHTHALMIC DISORDERS

7.9.2 ENDOCRINE DISORDERS

## 8 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE

### 8.1 INTRODUCTION

### 8.2 HOSPITALS

8.2.1 HOSPITALS TO HOLD LARGEST MARKET SHARE THROUGHOUT FORECAST PERIOD

### 8.3 AMBULATORY SURGERY CENTERS/CLINICS

8.3.1 INCREASING PREFERENCE FOR AMBULATORY CARE TO FUEL DEMAND FOR PHARMACEUTICAL DRUG DELIVERY TECHNOLOGIES

8.4 HOME CARE SETTINGS

8.4.1 HOME CARE SETTINGS TO REGISTER HIGHEST GROWTH RATE

8.5 DIAGNOSTIC CENTERS

8.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT MARKET GROWTH

8.6 OTHER FACILITIES OF USE

## **9 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION**

9.1 INTRODUCTION

9.2 NORTH AMERICA

9.2.1 US

9.2.1.1 US to dominate North American pharmaceutical drug delivery market

9.2.2 CANADA

9.2.2.1 Government support for research and rising prevalence of chronic diseases to drive market

9.3 EUROPE

9.3.1 GERMANY

9.3.1.1 Growing focus of pharmaceutical companies on developing innovative drug delivery products to drive market

9.3.2 FRANCE

9.3.2.1 Presence of leading pharmaceutical companies and rising prevalence of chronic diseases to drive market

9.3.3 ITALY

9.3.3.1 Increasing focus on clinical research and growing popularity of branded drugs to drive demand

9.3.4 UK

9.3.4.1 Increasing incidence and prevalence of chronic and infectious diseases to drive market

9.3.5 SPAIN

9.3.5.1 Increase in biologics production to support market growth

9.3.6 REST OF EUROPE

9.4 ASIA PACIFIC

9.4.1 CHINA

9.4.1.1 High diabetes incidence and favorable government initiatives to drive market

9.4.2 JAPAN

9.4.2.1 Favorable government initiatives and increased geriatric population to drive

market growth in Japan

#### 9.4.3 INDIA

9.4.3.1 Growing generic demand and rising government initiatives to drive market

#### 9.4.4 AUSTRALIA

9.4.4.1 Favorable government initiatives and outlook for pharma sector to support growth

#### 9.4.5 SOUTH KOREA

9.4.5.1 Growing pharmaceutical segment to support demand for delivery technologies

#### 9.4.6 REST OF ASIA PACIFIC

### 9.5 LATIN AMERICA

#### 9.5.1 BRAZIL

9.5.1.1 Investments and government support to attract multinational pharma companies to Brazil

#### 9.5.2 MEXICO

9.5.2.1 Growth and diversification in Mexico's pharmaceutical exports to drive market

#### 9.5.3 REST OF LATIN AMERICA

### 9.6 MIDDLE EAST & AFRICA

#### 9.6.1 GCC COUNTRIES

9.6.1.1 Rising healthcare expenditure to drive market growth

#### 9.6.2 REST OF MIDDLE EAST & AFRICA

## 10 COMPETITIVE LANDSCAPE

### 10.1 OVERVIEW

### 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN

10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PHARMACEUTICAL DRUG DELIVERY MARKET

### 10.3 REVENUE ANALYSIS

### 10.4 MARKET SHARE ANALYSIS

### 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023

#### 10.5.1 STARS

#### 10.5.2 EMERGING LEADERS

#### 10.5.3 PERVASIVE PLAYERS

#### 10.5.4 PARTICIPANTS

#### 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023

10.5.5.1 Company footprint

10.5.5.2 Route of administration footprint

10.5.5.3 Region footprint

- 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  - 10.6.1 PROGRESSIVE COMPANIES
  - 10.6.2 RESPONSIVE COMPANIES
  - 10.6.3 DYNAMIC COMPANIES
  - 10.6.4 STARTING BLOCKS
  - 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 10.7 VALUATION & FINANCIAL METRICS
  - 10.7.1 FINANCIAL METRICS
  - 10.7.2 COMPANY VALUATION
- 10.8 BRAND/PRODUCT COMPARISON
- 10.9 COMPETITIVE SCENARIO
  - 10.9.1 PRODUCT LAUNCHES & APPROVALS
  - 10.9.2 DEALS
  - 10.9.3 EXPANSIONS
  - 10.9.4 OTHER DEVELOPMENTS

## **11 COMPANY PROFILES**

- 11.1 KEY PLAYERS
  - 11.1.1 JOHNSON & JOHNSON SERVICES, INC.
    - 11.1.1.1 Business overview
    - 11.1.1.2 Products offered
    - 11.1.1.3 Recent developments
      - 11.1.1.3.1 Product approvals
      - 11.1.1.3.2 Deals
      - 11.1.1.3.3 Other developments
    - 11.1.1.4 MnM view
      - 11.1.1.4.1 Right to win
      - 11.1.1.4.2 Strategic choices
      - 11.1.1.4.3 Weaknesses and competitive threats
  - 11.1.2 NOVARTIS AG
    - 11.1.2.1 Business overview
    - 11.1.2.2 Products offered
    - 11.1.2.3 Recent developments
      - 11.1.2.3.1 Product approvals
      - 11.1.2.3.2 Deals
    - 11.1.2.4 MnM view
      - 11.1.2.4.1 Right to win
      - 11.1.2.4.2 Strategic choices

- 11.1.2.4.3 Weaknesses and competitive threats
- 11.1.3 F. HOFFMANN-LA ROCHE LTD.
  - 11.1.3.1 Business overview
  - 11.1.3.2 Products offered
  - 11.1.3.3 Recent developments
    - 11.1.3.3.1 Product approvals
    - 11.1.3.3.2 Deals
  - 11.1.3.4 MnM view
    - 11.1.3.4.1 Right to win
    - 11.1.3.4.2 Strategic choices
    - 11.1.3.4.3 Weaknesses and competitive threats
- 11.1.4 PFIZER INC.
  - 11.1.4.1 Business overview
  - 11.1.4.2 Products offered
  - 11.1.4.3 Recent developments
    - 11.1.4.3.1 Product approvals
    - 11.1.4.3.2 DEALS
  - 11.1.4.4 MnM view
    - 11.1.4.4.1 Right to win
    - 11.1.4.4.2 Strategic choices
    - 11.1.4.4.3 Weaknesses and competitive threats
- 11.1.5 BECTON, DICKINSON AND COMPANY
  - 11.1.5.1 Business overview
  - 11.1.5.2 Products offered
  - 11.1.5.3 Recent developments
    - 11.1.5.3.1 Product launches
    - 11.1.5.3.2 Other developments
  - 11.1.5.4 MnM view
    - 11.1.5.4.1 Right to win
    - 11.1.5.4.2 Strategic choices
    - 11.1.5.4.3 Weaknesses and competitive threats
- 11.1.6 GLAXOSMITHKLINE PLC
  - 11.1.6.1 Business overview
  - 11.1.6.2 Products offered
  - 11.1.6.3 Recent developments
    - 11.1.6.3.1 Product approvals
    - 11.1.6.3.2 Deals
    - 11.1.6.3.3 Other developments
- 11.1.7 MERCK & CO., INC.



- 11.1.7.1 Business overview
- 11.1.7.2 Products offered
- 11.1.7.3 Recent developments
  - 11.1.7.3.1 Product approvals
  - 11.1.7.3.2 Deals
- 11.1.8 SANOFI
  - 11.1.8.1 Business overview
  - 11.1.8.2 Products offered
  - 11.1.8.3 Recent developments
    - 11.1.8.3.1 Product approvals
    - 11.1.8.3.2 Deals
- 11.1.9 BAYER AG
  - 11.1.9.1 Business overview
  - 11.1.9.2 Products offered
  - 11.1.9.3 Recent developments
    - 11.1.9.3.1 Product approvals
    - 11.1.9.3.2 Deals
    - 11.1.9.3.3 Expansions
- 11.1.10 AMGEN, INC.
  - 11.1.10.1 Business overview
  - 11.1.10.2 Products offered
  - 11.1.10.3 Recent developments
    - 11.1.10.3.1 Product approvals
    - 11.1.10.3.2 Deals
- 11.1.11 ABBVIE INC.
  - 11.1.11.1 Business overview
  - 11.1.11.2 Products offered
  - 11.1.11.3 Recent developments
    - 11.1.11.3.1 Product launches & approvals
    - 11.1.11.3.2 Deals
    - 11.1.11.3.3 Expansions
- 11.1.12 GENMAB A/S
  - 11.1.12.1 Business overview
  - 11.1.12.2 Products offered
  - 11.1.12.3 Recent developments
    - 11.1.12.3.1 Product approvals
    - 11.1.12.3.2 Deals
- 11.1.13 GILEAD SCIENCES, INC.
  - 11.1.13.1 Business overview

- 11.1.13.2 Products offered
- 11.1.13.3 Recent developments
  - 11.1.13.3.1 Product approvals
  - 11.1.13.3.2 Deals
  - 11.1.13.3.3 Other developments
- 11.1.14 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  - 11.1.14.1 Business overview
  - 11.1.14.2 Products offered
  - 11.1.14.3 Recent developments
    - 11.1.14.3.1 Product approvals
    - 11.1.14.3.2 Deals
- 11.1.15 ASTRAZENECA
  - 11.1.15.1 Business overview
  - 11.1.15.2 Products offered
  - 11.1.15.3 Recent developments
    - 11.1.15.3.1 Product approvals
    - 11.1.15.3.2 Deals
- 11.1.16 ELI LILLY AND COMPANY
  - 11.1.16.1 Business overview
  - 11.1.16.2 Products offered
  - 11.1.16.3 Recent developments
    - 11.1.16.3.1 Product approvals
    - 11.1.16.3.2 Deals
    - 11.1.16.3.3 Expansions
- 11.1.17 TEVA PHARMACEUTICAL INDUSTRIES LTD.
  - 11.1.17.1 Business overview
  - 11.1.17.2 Products offered
  - 11.1.17.3 Recent developments
    - 11.1.17.3.1 Product approvals & launches
    - 11.1.17.3.2 Deals
- 11.2 OTHER PLAYERS
  - 11.2.1 NOVO NORDISK A/S
  - 11.2.2 GLENMARK PHARMACEUTICALS LTD.
  - 11.2.3 VIATRIS INC
  - 11.2.4 BRISTOL-MYERS SQUIBB COMPANY
  - 11.2.5 SANDOZ GROUP AG
  - 11.2.6 GERRESHEIMER AG
  - 11.2.7 BOSTON SCIENTIFIC CORPORATION
  - 11.2.8 CMP PHARMA

## 11.2.9 RUSAN PHARMA

## 12 APPENDIX

### 12.1 DISCUSSION GUIDE

### 12.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

### 12.3 CUSTOMIZATION OPTIONS

### 12.4 RELATED REPORTS

### 12.5 AUTHOR DETAILS

### TABLE 1 STANDARD EXCHANGE RATES FOR CONVERSION TO USD

### TABLE 2 US FDA: INDICATIVE LIST OF APPROVED BIOLOGICS (2023)

### TABLE 3 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

### TABLE 4 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

### TABLE 5 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

### TABLE 6 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

### TABLE 7 MIDDLE EAST: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

### TABLE 8 AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

### TABLE 9 IMPORT DATA FOR SYRINGES, WITH OR WITHOUT NEEDLES (HS CODE 901831), BY COUNTRY, 2019–2023 (USD THOUSAND)

### TABLE 10 EXPORT DATA FOR SYRINGES, WITH OR WITHOUT NEEDLES (HS CODE 901831), BY COUNTRY, 2019–2023 (USD THOUSAND)

### TABLE 11 IMPORT DATA FOR MEDICAMENTS IN MEASURED DOSES, INCLUDING TRANSDERMAL ADMINISTRATION (HS CODE 300490), BY COUNTRY,

### **2019–2023 (USD THOUSAND)**

### TABLE 12 EXPORT DATA FOR MEDICAMENTS IN MEASURED DOSES, INCLUDING TRANSDERMAL ADMINISTRATION (HS CODE 300490), BY COUNTRY,

### **2019–2023 (USD THOUSAND)**

### TABLE 13 INDICATIVE LIST OF PATENTS/PATENT APPLICATIONS IN PHARMACEUTICAL DRUG DELIVERY, 2023 –2024

TABLE 14 PHARMACEUTICAL DRUG DEVELOPMENT MARKET: PORTER'S FIVE FORCES ANALYSIS

TABLE 15 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS, BY END USER

TABLE 16 KEY BUYING CRITERIA, BY END USER

TABLE 17 AVERAGE SELLING PRICE TREND OF PHARMACEUTICAL DRUG DELIVERY PRODUCTS, BY REGION

TABLE 18 LIST OF MAJOR CONFERENCES & EVENTS IN 2024–2025

TABLE 19 US: REIMBURSEMENT CODES FOR INJECTION

TABLE 20 US: REIMBURSEMENT CODES FOR INHALER TECHNIQUES

TABLE 21 US: REIMBURSEMENT CODES FOR CHEMOTHERAPY ADMINISTRATION

TABLE 22 CASE STUDY 1: ADVANCEMENTS IN TREATING DEPRESSION WITH NOVEL AND RAPIDLY ACTING DRUG DELIVERY TECHNOLOGY

TABLE 23 CASE STUDY 2: OVERCOMING SUPPLY CHAIN ROADBLOCKS FOR RELIABLE COMPLEX ORAL SOLID DOSE (OSD) DELIVERY AT PFIZER CENTREONE, ASCOLI, ITALY

TABLE 24 PHARMACEUTICAL DRUG DELIVERY MARKET: END-USER EXPECTATIONS

TABLE 25 PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)

TABLE 26 INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 27 INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 28 CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY,

**2022–2029 (USD BILLION)**

TABLE 29 CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

**2022–2029 (USD BILLION)**

TABLE 30 GLASS SYRINGES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 31 PLASTIC SYRINGES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 32 CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

**2022–2029 (USD BILLION)**

TABLE 33 FILLABLE SYRINGES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 34 PREFILLED SYRINGES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 35 CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

**2022–2029 (USD BILLION)**

TABLE 36 REUSABLE SYRINGES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 37 DISPOSABLE SYRINGES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 38 SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 39 SELF-INJECTION DEVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 40 NEEDLE-FREE INJECTORS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 41 AUTOINJECTORS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 42 COMMERCIALY AVAILABLE PEN INJECTORS

TABLE 43 PEN INJECTORS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 44 WEARABLE INJECTORS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 45 ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 46 ORAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 47 SOLID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 48 SOLID ORAL DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 49 TABLETS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 50 CAPSULES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 51 ORAL POWDERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 52 PILLS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 53 LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 54 LIQUID ORAL DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 55 ORAL SYRUPS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 56 ORAL SOLUTIONS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 57 ORAL EMULSIONS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 58 ORAL ELIXIRS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 59 SEMI-SOLID ORAL DRUGS, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 60 SEMI-SOLID ORAL DRUGS, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 61 ORAL GELS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 62 ORAL PASTES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 63 TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 64 TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 65 SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 66 SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY COUNTRY,

**2022–2029 (USD BILLION)**

TABLE 67 TOPICAL CREAMS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 68 TOPICAL GELS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 69 TOPICAL OINTMENTS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 70 TOPICAL PASTES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 71 TOPICAL LOTIONS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 72 LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 73 LIQUID TOPICAL FORMULATIONS MARKET, BY COUNTRY,

**2022–2029 (USD BILLION)**

TABLE 74 TOPICAL SUSPENSIONS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 75 TOPICAL EMULSIONS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 76 TOPICAL SOLUTIONS MARKET, BY COUNTRY, 2022–2029 (USD

BILLION)

TABLE 77 SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 78 SOLID TOPICAL FORMULATIONS MARKET, BY COUNTRY,

**2022–2029 (USD BILLION)**

TABLE 79 TOPICAL POWDERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 80 SUPPOSITORIES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 81 TRANSDERMAL PRODUCTS MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 82 TRANSDERMAL PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 83 TRANSDERMAL PATCHES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 84 TRANSDERMAL GELS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 85 TRANSDERMAL SPRAYS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 86 OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 87 OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 88 LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 89 LIQUID OCULAR FORMULATIONS MARKET, BY COUNTRY,

**2022–2029 (USD BILLION)**

TABLE 90 COMMERCIALY AVAILABLE EYE DROPS

TABLE 91 EYE DROPS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 92 LIQUID OCULAR SPRAYS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 93 SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 94 SEMI-SOLID OCULAR FORMULATIONS MARKET, BY COUNTRY,

**2022–2029 (USD BILLION)**

TABLE 95 OCULAR GELS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 96 EYE OINTMENTS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 97 OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 98 OCULAR DEVICES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 99 OCULAR INSERTS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 100 DRUG-COATED CONTACT LENSES MARKET, BY COUNTRY,

**2022–2029 (USD BILLION)**

TABLE 101 PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 102 PULMONARY DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 103 METERED-DOSE INHALERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 104 DRY POWDER INHALERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 105 NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 106 NEBULIZERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 107 JET NEBULIZERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 108 ULTRASONIC NEBULIZERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 109 SOFT MIST NEBULIZERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 110 NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 111 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 112 NASAL SPRAYS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 113 NASAL DROPS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 114 NASAL GELS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 115 NASAL POWDERS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 116 TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029



(USD BILLION)

TABLE 117 TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY,

**2022–2029 (USD BILLION)**

TABLE 118 ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 119 ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY COUNTRY,

**2022–2029 (USD BILLION)**

TABLE 120 BUCCAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 121 SUBLINGUAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 122 OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 123 OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY COUNTRY,

**2022–2029 (USD BILLION)**

TABLE 124 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 125 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 126 IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 127 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 128 PASSIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY,

**2022–2029 (USD BILLION)**

TABLE 129 ACTIVE IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY,

**2022–2029 (USD BILLION)**

TABLE 130 PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,

**2022–2029 (USD BILLION)**

TABLE 131 PHARMACEUTICAL DRUG DELIVERY MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 132 LIST OF FDA-APPROVED DRUGS FOR ONCOLOGY (2024)

TABLE 133 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CANCER, BY COUNTRY,

**2022–2029 (USD BILLION)**

TABLE 134 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CVD, BY COUNTRY,

**2022–2029 (USD BILLION)**

TABLE 135 PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIABETES, BY COUNTRY,

**2022–2029 (USD BILLION)**

TABLE 136 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2023)

TABLE 137 PHARMACEUTICAL DRUG DELIVERY MARKET FOR RESPIRATORY DISEASES,

BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 138 PHARMACEUTICAL DRUG DELIVERY MARKET FOR CNS DISORDERS, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 139 PHARMACEUTICAL DRUG DELIVERY MARKET FOR AUTOIMMUNE DISEASES,

BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 140 PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 141 PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,

**2022–2029 (USD BILLION)**

TABLE 142 PHARMACEUTICAL DRUG DELIVERY MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 143 PHARMACEUTICAL DRUG DELIVERY MARKET FOR ASCS/CLINICS, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 144 PHARMACEUTICAL DRUG DELIVERY MARKET FOR HOME CARE SETTINGS,

BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 145 PHARMACEUTICAL DRUG DELIVERY MARKET FOR DIAGNOSTIC CENTERS,

BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 146 PHARMACEUTICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES OF USE,

BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 147 PHARMACEUTICAL DRUG DELIVERY MARKET, BY REGION,

**2022–2029 (USD BILLION)**

TABLE 148 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2029 (USD BILLION)

TABLE 149 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)

TABLE 150 NORTH AMERICA: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 151 NORTH AMERICA: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 152 NORTH AMERICA: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 153 NORTH AMERICA: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD MILLION)**

TABLE 154 NORTH AMERICA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 155 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL, 2022–2029 (USD BILLION)

TABLE 156 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT, 2022–2029 (USD BILLION)

TABLE 157 NORTH AMERICA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY, 2022–2029 (USD BILLION)

TABLE 158 NORTH AMERICA: SELF-INJECTION DEVICES MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 159 NORTH AMERICA: OCULAR DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 160 NORTH AMERICA: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 161 NORTH AMERICA: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 162 NORTH AMERICA: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 163 NORTH AMERICA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 164 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 165 NORTH AMERICA: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 166 NORTH AMERICA: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 167 NORTH AMERICA: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 168 NORTH AMERICA: TRANSDERMAL PRODUCTS MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 169 NORTH AMERICA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 170 NORTH AMERICA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 171 NORTH AMERICA: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 172 NORTH AMERICA: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 173 NORTH AMERICA: PULMONARY DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 174 NORTH AMERICA: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 175 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION, 2022–2029 (USD BILLION)

TABLE 176 NORTH AMERICA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2029 (USD BILLION)

TABLE 177 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)

TABLE 178 US: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 179 US: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 180 US: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029

(USD BILLION)

TABLE 181 US: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD MILLION)**

TABLE 182 US: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029  
(USD BILLION)

TABLE 183 US: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

**2022–2029 (USD BILLION)**

TABLE 184 US: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

**2022–2029 (USD BILLION)**

TABLE 185 US: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

**2022–2029 (USD BILLION)**

TABLE 186 US: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD  
BILLION)

TABLE 187 US: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD  
BILLION)

TABLE 188 US: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 189 US: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE  
FORM,

**2022–2029 (USD BILLION)**

TABLE 190 US: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 191 US: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 192 US: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD  
BILLION)

TABLE 193 US: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  
**2022–2029 (USD BILLION)**

TABLE 194 US: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE  
FORM,  
**2022–2029 (USD BILLION)**

TABLE 195 US: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,  
**2022–2029 (USD BILLION)**

TABLE 196 US: TRANSDERMAL PRODUCTS MARKET, BY TYPE, 2022–2029 (USD  
BILLION)

TABLE 197 US: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029  
(USD MILLION)

TABLE 198 US: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  
**2022–2029 (USD BILLION)**

TABLE 199 US: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  
**2022–2029 (USD BILLION)**

TABLE 200 US: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,  
**2022–2029 (USD BILLION)**

TABLE 201 US: PULMONARY DRUG DELIVERY MARKET, BY TYPE, 2022–2029  
(USD BILLION)

TABLE 202 US: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 203 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,  
**2022–2029 (USD BILLION)**

TABLE 204 US: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF  
USE,

**2022–2029 (USD BILLION)**

TABLE 205 CANADA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)

TABLE 206 CANADA: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 207 CANADA: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 208 CANADA: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 209 CANADA: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 210 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 211 CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

**2022–2029 (USD BILLION)**

TABLE 212 CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

**2022–2029 (USD BILLION)**

TABLE 213 CANADA: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

**2022–2029 (USD BILLION)**



TABLE 214 CANADA: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029  
(USD BILLION)

TABLE 215 CANADA: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029  
(USD BILLION)

TABLE 216 CANADA: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE  
FORM,

**2022–2029 (USD BILLION)**

TABLE 217 CANADA: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY  
DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 218 CANADA: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD  
BILLION)

TABLE 219 CANADA: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 220 CANADA: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029  
(USD BILLION)

TABLE 221 CANADA: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE  
FORM,

**2022–2029 (USD BILLION)**

TABLE 222 CANADA: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY  
DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 223 CANADA: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE  
FORM,

**2022–2029 (USD BILLION)**

TABLE 224 CANADA: TRANSDERMAL PRODUCTS MARKET, BY TYPE

**2022–2029 (USD BILLION)**

TABLE 225 CANADA: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD MILLION)**

TABLE 226 CANADA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,  
**2022–2029 (USD BILLION)**

TABLE 227 CANADA: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY  
TYPE,

**2022–2029 (USD BILLION)**

TABLE 228 CANADA: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY  
TYPE,

**2022–2029 (USD MILLION)**

TABLE 229 CANADA: PULMONARY DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 230 CANADA: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 231 CANADA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY  
APPLICATION,

**2022–2029 (USD BILLION)**

TABLE 232 CANADA: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY  
OF USE,

**2022–2029 (USD BILLION)**

TABLE 233 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY  
COUNTRY,

**2022–2029 (USD BILLION)**

TABLE 234 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE  
OF ADMINISTRATION, 2022–2029 (USD BILLION)

TABLE 235 EUROPE: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 236 EUROPE: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  
**2022–2029 (USD BILLION)**

TABLE 237 EUROPE: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,  
**2022–2029 (USD BILLION)**

TABLE 238 EUROPE: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,  
**2022–2029 (USD BILLION)**

TABLE 239 EUROPE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,  
**2022–2029 (USD BILLION)**

TABLE 240 EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY  
MATERIAL,  
**2022–2029 (USD BILLION)**

TABLE 241 EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY  
PRODUCT,  
**2022–2029 (USD BILLION)**

TABLE 242 EUROPE: CONVENTIONAL INJECTION DEVICES MARKET, BY  
USABILITY,  
**2022–2029 (USD BILLION)**

TABLE 243 EUROPE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029  
(USD BILLION)

TABLE 244 EUROPE: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029  
(USD BILLION)

TABLE 245 EUROPE: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE  
FORM,

**2022–2029 (USD BILLION)**

TABLE 246 EUROPE: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 247 EUROPE: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 248 EUROPE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 249 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 250 EUROPE: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 251 EUROPE: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 252 EUROPE: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 253 EUROPE: TRANSDERMAL PRODUCTS MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 254 EUROPE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 255 EUROPE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 256 EUROPE: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 257 EUROPE: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 258 EUROPE: PULMONARY DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 259 EUROPE: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 260 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,

**2022–2029 (USD BILLION)**

TABLE 261 EUROPE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2029 (USD BILLION)

TABLE 262 GERMANY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)

TABLE 263 GERMANY: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 264 GERMANY: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 265 GERMANY: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 266 GERMANY: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 267 GERMANY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 268 GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

**2022–2029 (USD BILLION)**

TABLE 269 GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

**2022–2029 (USD BILLION)**

TABLE 270 GERMANY: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

**2022–2029 (USD BILLION)**

TABLE 271 GERMANY: SELF-INJECTION DEVICES MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 272 GERMANY: OCULAR DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 273 GERMANY: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 274 GERMANY: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 275 GERMANY: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 276 GERMANY: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 277 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 278 GERMANY: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 279 GERMANY: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 280 GERMANY: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 281 GERMANY: TRANSDERMAL PRODUCTS MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 282 GERMANY: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD MILLION)**

TABLE 283 GERMANY: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 284 GERMANY: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 285 GERMANY: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,

**2022–2029 (USD MILLION)**

TABLE 286 GERMANY: PULMONARY DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 287 GERMANY: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 288 GERMANY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,

**2022–2029 (USD BILLION)**

TABLE 289 GERMANY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2029 (USD BILLION)

TABLE 290 FRANCE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)

TABLE 291 FRANCE: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 292 FRANCE: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 293 FRANCE: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 294 FRANCE: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 295 FRANCE: INJECTABLE DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 296 FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

**2022–2029 (USD BILLION)**

TABLE 297 FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY

*Pharmaceutical Drug Delivery Market by Route of Administration [Oral, Injectors (Pen, Auto Injectors) Implanta...*



PRODUCT,

**2022–2029 (USD BILLION)**

TABLE 298 FRANCE: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

**2022–2029 (USD BILLION)**

TABLE 299 FRANCE: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 300 FRANCE: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 301 FRANCE: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 302 FRANCE: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 303 FRANCE: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 304 FRANCE: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 305 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 306 FRANCE: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 307 FRANCE: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 308 FRANCE: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 309 FRANCE: TRANSDERMAL PRODUCTS MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 310 FRANCE: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD MILLION)**

TABLE 311 FRANCE: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 312 FRANCE: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 313 FRANCE: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,

**2022–2029 (USD MILLION)**

TABLE 314 FRANCE: PULMONARY DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 315 FRANCE: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 316 FRANCE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,

**2022–2029 (USD BILLION)**

TABLE 317 FRANCE: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,

**2022–2029 (USD BILLION)**

TABLE 318 ITALY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF

*Pharmaceutical Drug Delivery Market by Route of Administration [Oral, Injectors (Pen, Auto Injectors) Implanta...*

ADMINISTRATION, 2022–2029 (USD BILLION)

TABLE 319 ITALY: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 320 ITALY: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 321 ITALY: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 322 ITALY: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 323 ITALY: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029  
(USD BILLION)

TABLE 324 ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

**2022–2029 (USD BILLION)**

TABLE 325 ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

**2022–2029 (USD BILLION)**

TABLE 326 ITALY: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

**2022–2029 (USD BILLION)**

TABLE 327 ITALY: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD  
BILLION)

TABLE 328 ITALY: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD  
BILLION)

TABLE 329 ITALY: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE  
FORM,

**2022–2029 (USD BILLION)**

TABLE 330 ITALY: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 331 ITALY: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 332 ITALY: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 333 ITALY: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 334 ITALY: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 335 ITALY: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 336 ITALY: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 337 ITALY: TRANSDERMAL PRODUCTS MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 338 ITALY: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD MILLION)**

TABLE 339 ITALY: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 340 ITALY: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 341 ITALY: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,

**2022–2029 (USD MILLION)**

TABLE 342 ITALY: PULMONARY DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 343 ITALY: NEBULIZERS MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 344 ITALY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY APPLICATION,

**2022–2029 (USD BILLION)**

TABLE 345 ITALY: PHARMACEUTICAL DRUG DELIVERY MARKET, BY FACILITY OF USE,

**2022–2029 (USD BILLION)**

TABLE 346 UK: PHARMACEUTICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)

TABLE 347 UK: ORAL DRUG DELIVERY MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 348 UK: SOLID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 349 UK: LIQUID ORAL DRUGS MARKET, BY DOSAGE FORM, 2022–2029 (USD BILLION)

TABLE 350 UK: SEMI-SOLID ORAL DRUGS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 351 UK: INJECTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 352 UK: CONVENTIONAL INJECTION DEVICES MARKET, BY MATERIAL,

**2022–2029 (USD BILLION)**

TABLE 353 UK: CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,

**2022–2029 (USD BILLION)**

TABLE 354 UK: CONVENTIONAL INJECTION DEVICES MARKET, BY USABILITY,

**2022–2029 (USD BILLION)**

TABLE 355 UK: SELF-INJECTION DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 356 UK: OCULAR DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 357 UK: LIQUID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 358 UK: SEMI-SOLID OCULAR FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 359 UK: OCULAR DEVICES MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 360 UK: NASAL DRUG DELIVERY MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 361 UK: TOPICAL DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 362 UK: LIQUID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 363 UK: SEMI-SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 364 UK: SOLID TOPICAL FORMULATIONS MARKET, BY DOSAGE FORM,

**2022–2029 (USD BILLION)**

TABLE 365 UK: TRANSDERMAL PRODUCTS MARKET, BY TYPE, 2022–2029 (USD BILLION)

TABLE 366 UK: IMPLANTABLE DRUG DELIVERY MARKET, BY TYPE, 2022–2029 (USD MILLION)

TABLE 367 UK: TRANSMUCOSAL DRUG DELIVERY MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 368 UK: ORAL TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,

**2022–2029 (USD BILLION)**

TABLE 369 UK: OTHER TRANSMUCOSAL FORMULATIONS MARKET, BY TYPE,

**2022–2029 (USD MILLION)**

## I would like to order

Product name: Pharmaceutical Drug Delivery Market by Route of Administration [Oral, Injectors (Pen, Auto Injectors) Implantable, Syrups, Gels, Pulmonary, Tablets, Syringes], Application (Cancer, Diabetes), Facility of Use (Hospital, Home Care) -Global Forecast to 2029

Product link: <https://marketpublishers.com/r/DFAB11EB95DEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DFAB11EB95DEN.html>